Company intelligence / Profile preview
Affinity Biopharmaceutical
Shanghai, Shanghai, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Affinity Biopharmaceutical is a clinical-stage company developing tumor microenvironment-activated therapeutics—including small molecule-drug conjugates, antibody-drug conjugates, and immune cell engagers—with its leading asset, doxorubicin (Legubicin), in Phase 2 for gastric cancer and at least one program in Phase 3 for soft tissue sarcoma
- Therapeutic areas
- Oncology
- Modalities
- Small molecule-drug conjugateAntibody-drug conjugateBispecific T cell engagerProteinCytokineAntibody
- Industry
- Biotech
02
Drug pipeline
31 assets30 more assets in the full pipeline.
Request access →03
Partnerships
Academic collaborationsPharmaceutical/biotech partnerships
Beyond the preview
Go deeper on Affinity Biopharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Affinity Biopharmaceutical.